ID   CC-LP-1
AC   CVCL_0205
SY   CC-LP-I; CCLP-1; CCLP1
DR   BTO; BTO:0002933
DR   MCCL; MCC:0000094
DR   cancercelllines; CVCL_0205
DR   Cell_Model_Passport; SIDM01889
DR   Cosmic; 927189
DR   DepMap; ACH-001959
DR   TOKU-E; 4041
DR   Wikidata; Q54808710
RX   CelloPub=CLPUB00275;
RX   PubMed=1355757;
RX   PubMed=27231123;
RX   PubMed=35640676;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 180 hours (PubMed=1355757).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (DepMap).
CC   Caution: Indicated to derive from a female patient in PubMed=1355757, but has a X,Y amelogenin STR marker.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): DepMap
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 9,12
ST   D16S539: 9,13
ST   D18S51: 13,14
ST   D21S11: 29,33
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 11,13
ST   FGA: 22
ST   Penta D: 12,13
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=1355757; DOI=10.1002/ijc.2910520217;
RA   Shimizu Y., Demetris A.J., Gollin S.M., Storto P.D., Bedford H.M.,
RA   Altarac S., Iwatsuki S., Herberman R.B., Whiteside T.L.;
RT   "Two new human cholangiocarcinoma cell lines and their cytogenetics
RT   and responses to growth factors, hormones, cytokines or immunologic
RT   effector cells.";
RL   Int. J. Cancer 52:252-260(1992).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   El-Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//